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Introduction 12 
The term ‘paroxysmal dyskinesia’ (PD) describes a manifestation of abnormal involuntary 13 
muscle contraction which by definition is episodic in nature and self-limiting (Lowrie & 14 
Garosi 2017). There have been numerous published articles concerning PDs over recent 15 
years and the earliest report in veterinary literature dates back to 1942 concerning 16 
‘Scottie Cramp’ in Scottish terriers (Klarenbeek 1942). Despite this, PDs remain a 17 
poorly understood and frequently under-recognised condition in veterinary patients 18 
(Richter et al. 2015; Strain 2016). Some useful terminology when considering this 19 
subject is included in table one. The purpose of this article is to review the basic 20 
classification and principles of recognition and diagnosis of PDs. This article will also 21 
introduce some of the breed-specific PDs, as well as the treatment/management options 22 
available and expected outcomes.  23 
 24 
PDs encompass a number of clinical signs with specific terminology, as detailed in table two 25 
(Kent 2012). Dystonia tends to be the most common clinical sign which is characterised 26 
by sustained and often repetitive muscle contraction in one or several limbs (Lowrie & 27 
Garosi 2017). This results in abnormal postures or twisting and tremor-like movements 28 
(Richter et al. 2015), which can initially appear confusing and alarming to owners and 29 
veterinary surgeons alike. Affected animals may collapse and become recumbent as a 30 
result of their dystonic movements, but they will frequently remain standing and 31 
responsive to their external environment (Platt 2016). For example, affected animals 32 
may continue to attempt engagement in play or show interest in food (figure one). PDs 33 
can last from seconds to hours, often with an abrupt beginning and end (Lowrie & 34 
Garosi 2017). They occur in the conscious animal and neurological examination is 35 
typically normal between episodes. PDs may be triggered by stress, exercise or 36 
excitement. There are also reports of drug-induced PDs (Kube et al. 2006; Mitek et al. 37 
2013). The remainder of this article will largely concern primary PDs.  38 
 39 
Current understanding suggests PDs are most likely the result of transient abnormal activity 40 
within deep collections of grey matter within the cerebral hemispheres (Lowrie & 41 
Garosi 2017); these areas are otherwise known as basal nuclei and are important in 42 
initiation and control of motor activity. Findings which help to support this theory 43 
include identification of lesions within the basal nuclei of patients with PDs (Bhatia & 44 
Marsden 1994; Gernert et al. 2000) and hyperactivity within basal nuclei during PD 45 
episodes, diagnosed using single photon emission computed tomography (Berti et al. 46 
2011). Despite this evidence, the underlying cause of PDs remains controversial and ion 47 
channelopathies, as well as functional imbalances of neurotransmitters within the brain, 48 
are also implicated in their pathogenesis (Lee 1979). PDs have been linked to epilepsy 49 
on a pathophysiological basis (Crompton & Berkovic 2009) although PDs and epilepsy 50 
are now regarded as two very separate disorders.   51 
 52 
Classification 53 
Numerous clinical classification systems have been suggested in recent years for PDs. One of 54 
the more widely known classification systems adapted from human literature identifies 55 
three main groups of PDs: paroxysmal kinesigenic (action-induced) dyskinesia (PKD), 56 
paroxysmal non-kinesigenic dyskinesia (PNKD) and paroxysmal exertion-induced 57 
dyskinesia (PED) (Waln & Jankovic 2015). The details and differentiating features of 58 
each classification group are detailed in table three. Although it is useful to have an 59 
awareness of the characteristic features of each of these classification groups, the 60 
majority of cases in veterinary medicine are consistent with PNKD. Therefore, the direct 61 
clinical relevance of this human classification is currently unclear. An additional sub-62 
classification for veterinary patients was recently proposed based on suspected aetiology 63 
of PDs, which may have more relevant clinical application (Lowrie & Garosi 2017).  64 
(1) Genetic causes – A genetic mutation of the brevican gene (BCAN) is implicated in 65 
episodic falling syndrome in Cavalier King Charles Spaniels (Gill et al. 2012). A 66 
mutation has also been identified in the PIGN gene which is linked to a PD in Soft-67 
coated Wheaten terriers (Kolicheski et al. 2017).  68 
(2) Dietary causes – Paroxysmal gluten sensitive dyskinesia (PGSD) is a type of PNKD 69 
well characterised in Border terriers (Black et al. 2014; Lowrie et al. 2018). The 70 
disorder shows a variable response to a gluten free diet with complete resolution of 71 
clinical signs in some cases (Lowrie et al. 2015).   72 
(3) Secondary causes – Previous reports exist of PDs which occurred as a result of 73 
phenobarbital administration (Kube et al. 2006), or following the use of propofol 74 
(Mitek et al. 2013). 75 
(4) Presumed genetic/ unidentified causes – An autosomal recessive mode of inheritance 76 
is presumed in several breed-related PDs, which have characteristic phenotypic 77 
features. These include ‘Scottie Cramp’ in Scottish terriers, as well as a familial 78 
occurrence of PDs reported in the Chinook breed of dog ( Lowrie & Garosi 2016; 79 
Packer et al. 2010; Urkasemsin & Olby 2015). As of yet, no definitive genetic cause 80 
has been identified in these breeds, which can be directly linked to PDs.   81 
 82 
Diagnosis 83 
Diagnosis of PDs is often speculative and based on observation and assessment of key 84 
features of abnormal events. Due to the intrinsic nature of PDs, which are episodic and 85 
sometimes situation-specific, they are rarely observed on presentation to a veterinary 86 
surgeon. Video recording and documentation of abnormal events has aided diagnosis in 87 
recent years with increased accessibility to smart-phone technology to record abnormal 88 
events at home. The marked heterogeneity and overlap with other transient disorders in 89 
terms of clinical features, can make accurate identification and recognition of PDs 90 
challenging (Lowrie & Garosi 2017). In addition, the co-occurrence of PDs with 91 
conditions such as epilepsy as seen in the Chinook dogs can further add to the diagnostic 92 
challenge associated with PDs (Packer et al. 2010).  93 
 94 
Differential diagnosis for PDs can include seizure episodes, neuromuscular disease, 95 
idiopathic tremors, tetanic spasms, narcoleptic/cataplexic disorders, vestibular attacks, 96 
syncopal episodes, acute pain syndrome, and paroxysmal behavioural episodes (Richter 97 
et al. 2015). This list is by no means exhaustive and all of the above should be 98 
considered when making a diagnosis of PD. Table four identifies some of the main 99 
differentiating features between PDs and seizure episodes. One of the main challenges is 100 
the differentiation of PDs from simple focal seizures, which like PDs, are not associated 101 
with impaired consciousness. In contrast, simple focal seizures are often associated with 102 
obvious lateralisation of clinical signs due to unilateral cerebral involvement, while PDs 103 
often result in more generalised signs involving all limbs/both sides of the body. 104 
Although it is important to be aware of the limitations and potential inaccuracies of 105 
diagnosing by observation alone, it is a useful first step in identifying PDs.  106 
 107 
The availability of advanced imaging along with time-consuming or invasive diagnostics 108 
(e.g. cerebrospinal fluid analysis and electrodiagnostics) is often limited in general 109 
practice, yet this does not preclude the possibility of making an accurate diagnosis of 110 
PDs (Lowrie & Garosi 2017). Advanced diagnostics are frequently of limited value 111 
when making a diagnosis of PDs and often ‘unremarkable’. Accurate clinical reasoning 112 
and judgement is vital when considering a case with possible PDs. Definitive diagnostic 113 
tests exist for very few PDs but serological testing in Border terriers for example, or 114 
genetic testing in Cavalier King Charles Spaniels and Soft-coated Wheaten terriers is 115 
available for breed-specific conditions and can easily be performed in a general practice 116 
setting. It is essential to obtain a thorough clinical history, full physical and neurological 117 
examination, in addition to obtaining a minimum database (routine blood work and 118 
urinalysis) as part of the diagnostic workup.  119 
 120 
Breed-specific PDs in dogs (table five) 121 
A. Paroxysmal dyskinesia of Scottish terriers (Scottie Cramp) 122 
This episodic hyperkinetic syndrome described in this breed is now classified as a PNKD 123 
(Klarenbeek 1942; Lowrie & Garosi 2017). Clinical signs become evident from one 124 
month to seven years of age and females are overrepresented. Clinical signs consist of 125 
hypertonicity, arching of the lumbar spine, a stiff gait, flexion of the pelvic limbs, 126 
abduction of the thoracic limbs, dystonic postures (pillar-like stance, curling into a 127 
ball), skipping steps, and difficulty/inability to walk (Meyers 1970; Urkasemsin & 128 
Olby 2015). An autosomal-recessive inheritance pattern is presumed (Meyers 1970) 129 
and a defect in serotonin metabolism has been proposed as a possible cause of these 130 
episodes but the exact pathophysiological mechanism remains unknown (Meyers & 131 
Schab 1974; Peters & Meyers 1977). This is a non-progressive disease and severity 132 
can decrease with time. Avoidance of precipitating factors, such as excitement or 133 
stress, can help to reduce the frequency of episodes. Diazepam or acepromazine 134 
maleate can be used, but fluoxetine appears to be more effective in reducing the 135 
frequency and duration of the episodes (Geiger & Klopp 2009; Urkasemsin & Olby 136 
2015). 137 
 138 
B. Paroxysmal gluten-sensitive dyskinesia (PGSD) of Border terriers (BT)   139 
PGSD is another term for a multisystem disorder previously known as canine epileptoid 140 
cramping syndrome (CECS) in BTs. An association between gluten sensitivity and 141 
this characteristic PD was demonstrated in BTs (Lowrie et al. 2018; Lowrie et al. 142 
2015). Age of onset is six weeks to nine years (Black et al. 2014; Lowrie et al. 2018; 143 
Stassen et al. 2017). Dystonia of the limbs/ head/ neck, tremors, ataxia, difficulty 144 
walking, and inability to maintain a standing position are common associated findings 145 
and are often accompanied by borborygmi (Black et al. 2014; Lowrie et al. 2018; 146 
Lowrie & Garosi 2017; Lowrie et al. 2015; Urkasemsin & Olby 2015). Signs 147 
preceding the event include attention seeking, vomiting, and eating grass (Black et al. 148 
2014). Concurrent dermatological and gastrointestinal disease is possible as seen in 149 
people with gluten sensitivity (Black et al. 2014; Hadjivassiliou et al. 2003; Lowrie et 150 
al. 2018). No genetic mutation could be identified in a cohort of 110 dogs indicating a 151 
complex mode of inheritance (Stassen et al. 2017). A link between dietary exclusion 152 
of gluten and resolution of clinical signs was shown (Lowrie et al. 2015). Serological 153 
testing for anti-transglutaminase-2 and anti-gliadin antibodies in addition to the 154 
clinical signs can aid diagnosis. However, these serological markers are not exclusive 155 
to PGSD (Lowrie et al. 2018).  Institution of a strictly gluten-free diet can serve as a 156 
diagnostic and therapeutic tool (Lowrie et al. 2015; Lowrie et al. 2016). Possible 157 
PGSD has also been reported in a Yorkshire terrier (Park et al. 2014). 158 
 159 
C. Episodic falling syndrome of Cavalier King Charles Spaniels (CKCS) 160 
This familial PD is also known under the term ‘episodic hypertonicity of Cavalier King 161 
Charles Spaniels’ (Garosi et al 2002). There is currently disagreement in veterinary 162 
literature about whether this is a non-kinesigenic or exertion-induced PD (Forman et 163 
al. 2012; Lowrie & Garosi 2017). Age of onset is three months to four years. Ataxic 164 
pelvic limb gait, abduction of the limbs, progressive muscular hypertonicity, dystonic 165 
postures (arching of the spine, ‘deer-stalking’ or ‘praying’ posture), ‘bunny hopping’ 166 
and collapse are common associated clinical signs (Forman et al. 2012; Gill et al. 167 
2012; Herrtage & Palmer 1983). An autosomal recessive mode of inheritance is 168 
suspected with around 13% of CKCS carrying the causative genetic mutation 169 
(Forman et al. 2012; Gill et al. 2012). A deletion involving the BCAN gene, which 170 
encodes an aggregating extracellular matrix proteoglycan has been demonstrated. 171 
DNA testing is available for diagnostic purposes but long-term may also be useful in 172 
the elimination of carrier dogs from breeding programs. Episodic hypertonicity can be 173 
a self-limiting disease in CKCS. Clonazepam can result in improvement of clinical 174 
signs although tolerance can occur with long-term therapy and acetazolamide 175 
represents an alternative therapeutic option (Forman et al. 2012; Garosi et al. 2002; 176 
Gill et al. 2012).  177 
 178 
D. Paroxysmal dyskinesia of Soft-coated Wheaten terriers (SCWT) 179 
Episodic dystonic movements and postures are reported in this breed as part of a familial PD. 180 
Age of onset is typically between eight months and three years (Kolicheski et al. 181 
2017; O’Brien et. al 2015). Episodes are characterised by rapid flexion and extension 182 
of pelvic limbs with truncal dystonia and progressive involvement of thoracic limbs in 183 
severe cases (Kolicheski et al. 2017). An autosomal recessive trait of inheritance was 184 
proposed and a mutation in the gene PIGN was demonstrated. The diagnosis can be 185 
confirmed by DNA testing. Thus far, there is no proven benefit to treatment with 186 
benzodiazepines, antiepileptic drugs and muscle relaxants. Clinical signs may be 187 
progressive over time (Kolicheski et al. 2017; O’Brien et. al 2015; Shelton 2004) but 188 
medical therapy with acetazolamide has been shown to be effective with some dogs 189 
achieving complete resolution of the dyskinesia (O’Brien et. al 2015). 190 
 191 
E. Paroxysmal dyskinesia of Labrador retrievers  192 
 Episodes of dystonic involuntary movements and postures, resembling typical clinical 193 
features of PD, are occasionally reported in this breed. Age of onset is from nine 194 
months to ten years eight months and the majority of affected dogs are males. No 195 
genetic associations were investigated yet and the pathogenesis remains unknown. 196 
There is no specific treatment for PDs in this breed but a natural reduction in episode 197 
frequency was reported in the majority of dogs and spontaneous remission is possible 198 
(Lowrie & Garosi 2016). 199 
 200 
G. Paroxysmal dyskinesia of Jack Russell terriers (JRT) 201 
The natural history of PDs in JRTs was recently described. Age of onset was from one to 202 
eight years. Extremes of temperature preceded the episodes in 83% of dogs. Disease 203 
severity decreased over time in 57% of dogs and late spontaneous remission was 204 
achieved in 22% of dogs. The mode of inheritance and pathogenesis remain unknown. 205 
There is no specific treatment for this PD in JRTs (Lowrie & Garosi 2016). 206 
 207 
H. Paroxysmal dyskinesia of Chinooks 208 
A familial PD has been reported in this breed. Most dogs develop signs within their first three 209 
years of life. Affected dogs are unable to stand or walk during the episodes. Head 210 
tremors, flexion of one or more limbs, dystonia, repetitive limb contractions, and 211 
collapse were reported. An autosomal recessive or polygenic pattern of inheritance is 212 
suspected based on pedigree analysis. Interestingly, the same breed lines, which 213 
suffered with PDs were found to suffer from epilepsy, but these two conditions appear 214 
to coexist in some dogs. There is no known treatment (Packer et al. 2010). 215 
 216 
I. Sporadic reports of paroxysmal dyskinesia in other breeds 217 
Typical paroxysmal dyskinetic events were reported in several other breeds including Wire-218 
haired terrier, Norwich terrier, Dalmatians, West Highland White terriers, Cairn 219 
terriers, Norwich terriers and Bichon Frise (De Risio & Freeman 2015; Penderis & 220 
Franklin 2001; Urkasemsin & Olby 2015; Woods 1977). Episodic hypertonicity was 221 
also seen in Springer Spaniels and Boxer puppies (Ramsey et al. 1999; Shelton 2004). 222 
A 12-week-old female Golden Retriever with suspected PD was treated successfully 223 
with acetazolamide (Royaux et al. 2015). A phenobarbital-responsive PD was 224 
reported in a German shorthaired pointer (GSHP) (Harcourt-Brown 2008). In a recent 225 
publication, anecdotal evidence of another GSHP with similar signs that achieved full 226 
remission after phenobarbital therapy was presented (Lowrie & Garosi 2017). 227 
 228 
Closing Comments 229 
PDs comprise a heterogeneous group of disorders with a high degree of phenotypic 230 
variability. Video footage and documentation of abnormal episodes can be extremely 231 
useful as a first step in identification of PDs. Accurate clinical reasoning and 232 
judgement is vital when considering a case with possible PDs and differentiation from 233 
other paroxysmal disorders, for example seizure episodes, can be challenging.  234 
Although there are several breed-related PDs which are well characterised, PDs may 235 
occur in any breed and they remain a poorly understood and frequently under-236 
recognised condition in veterinary patients. A genetic and/or pathophysiological 237 
classification would not only facilitate the diagnosis of PDs, but it may also support 238 
the development of new therapeutic approaches.  239 
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  384 
Table one – Useful terms when considering the subject of PDs 385 
Paroxysmal A sudden occurrence or intensification of clinical signs 
which is episodic in nature 
Dyskinesia Impairment or abnormal voluntary movement 
Movement Disorder A condition affecting the ability of an individual to 
initiate or control movement, often resulting in 
abnormal voluntary/involuntary movements 
Paroxysmal kinesigenic 
dyskinesia (PKD) 
A form of PDs precipitated by sudden movement 
Paroxysmal non-kinesigenic 
dyskinesia (PNKD)  
A form of PDs associated with stress or excitement, but 
not precipitated by movement 
Paroxysmal exertion-induced 
dyskinesia (PED) 
A form of PDs associated with heavy exercise  
  386 
Table two – Clinical signs associated with PDs and their definitions  387 
Dystonia Sustained involuntary muscle contraction causing abnormal 
postures 
Athetosis Prolonged, slow, involuntary contraction involving musculature 
of the trunk causing writhing and contortion of the body 
Chorea Unsustained involuntary muscle contraction causing abrupt 
movements 
Choreoathetosis Involuntary muscle contraction involving a combination of the 
athetosis and chorea 
Ballism Abrupt contraction of limb musculature causing flailing 
movements of the limbs, often unilateral 
  
 388 
  389 
Table three – Summary of the key features associated with the three main categories of 390 
PDs based on a human classification system 391 
  392 
Feature PKD PNKD PED 
Trigger Sudden movement Stress, caffeine, alcohol Heavy exercise 
Age of onset Childhood/adolescent Childhood/adolescent Variable  
Duration  < 5 minutes  2 – 4 minutes 5 minutes – 2 hours 
Frequency  Variable – multiple 
attacks per day, may 
improve with age 
Variable - several per 
week to several in a 
lifetime 
Dependant on 
exercise 
Treatment Anticonvulsants 
including 
carbamazepine 
Trigger avoidance, 
benzodiazepines 
Trigger avoidance, 
ketogenic diet, 
gabapentin 
PKD, paroxysmal kinesigenic dyskinesia; PNKD, paroxysmal non-kinesigenic dyskinesia; 
PED, paroxysmal exertion-induced dyskinesia. 
Table four – Differentiating clinical characteristics of PDs and seizure episodes 393 
Paroxysmal Dyskinesia Seizure Episode 
No impairment of consciousness Reduced/ absent conscious responses 
No autonomic signs Autonomic signs may be present, e.g. 
hypersalivation, urination/defecation 
Usually abrupt onset Possible prodromal behavioural 
abnormalities  
No abnormal post-ictal behaviours Post-ictal behavioural changes may be 
present 
Variable duration (seconds to hours) Usually of short duration (<5 minutes)  
Unremarkable neurological examination in 
between episodes 
Possible persistent/ transient inter-ictal 
neurological abnormalities  
  394 
Table five – Breed specific PDs 395 
Breed 
specific PD 
Reported 
age of 
onset 
Suspected 
mode of 
inheritance 
Genetic 
mutation 
DNA 
test 
Treatment Prognosis 
Scottie 
Cramp 
One 
month to 
seven 
years 
Autosomal 
recessive 
Currently 
unknown 
No 
Fluoxetine 
Acepromazine 
Diazepam 
Fair prognosis: 
non-progressive 
disease, severity can 
decrease with time 
PGSD/CECS 
of Border 
terriers 
Six weeks 
to nine 
years 
Currently 
unknown 
Currently 
unknown 
No§ Gluten-free diet 
Good prognosis: 
variable but 
generally good 
response to gluten-
free diet 
Episodic 
falling 
syndrome of 
CKCS 
Three 
months to 
four years 
Autosomal 
recessive 
BCAN 
gene 
Yes\ 
Clonazepam, 
acetazolamide 
Good prognosis: it 
can be a self-
limiting disease 
PD of Soft-
coated 
Wheaten 
terrier 
Median: 
two years 
Autosomal 
recessive 
PIGN 
gene 
Yes Acetazolamide 
Guarded prognosis 
without treatment: 
generally 
progressive disease; 
Fair prognosis with 
treatment: 
improvement or 
resolution of signs is 
possible. 
PD of 
Labrador 
retrievers 
Nine 
months to 
ten years 
eight 
months 
Currently 
unknown 
Currently 
unknown 
No 
No known 
treatment* 
 
Good prognosis: 
reduction in episode 
frequency can be 
seen in the majority 
of dogs and 
spontaneous 
remission is possible 
PD of JRT 
One to 
eight years 
Currently 
unknown 
Currently 
unknown 
No 
No known 
treatment* 
Fair prognosis: 
Disease severity can 
decrease over time 
in some dogs and 
late spontaneous 
remission is possible  
PD of 
Chinooks 
 
Two 
months to 
five years 
Autosomal 
recessive or 
polygenic 
trait 
Currently 
unknown 
No 
No known 
treatment* 
Unknown 
* Medications such as clonazepam, acetazolamide or fluoxetine can be trialled for PD if episode frequency is not 396 
satisfactory.  397 
§ Serological testing is available (anti-transglutaminase-2 IgA and anti-gliadin IgG antibodies).  398 
\ A number of homozygous dogs remain asymptomatic. 399 
  400 
Figure one – a) dystonia, choreoathetosis and ballism, exhibited by an 18 month-old male 401 
neutered Labrador retriever; b) dystonia and choreoathetosis resulting in collapse and 402 
recumbency in a 4 year-old male entire Yorkshire terrier. 403 
 404 
